How the FDA Drug Approval Process Works

The U.S. Food and Drug Administration's drug approval process governs how every prescription medication legally reaches patients — from the first laboratory synthesis through decades of post-market surveillance. This page explains the statutory framework, sequential phases, regulatory classifications, and institutional tradeoffs that define the system. Understanding these mechanics is foundational for anyone analyzing pharmaceutical policy, clinical research timelines, or federal regulatory authority.

• Definition and scope
• Core mechanics or structure
• Causal relationships or drivers
• Classification boundaries
• Tradeoffs and tensions
• Common misconceptions
• Checklist or steps (non-advisory)
• Reference table or matrix

Definition and scope

The FDA drug approval process is the regulatory pathway by which the Center for Drug Evaluation and Research (CDER) determines whether a new pharmaceutical product is safe and effective for its intended use in the U.S. market. Legal authority derives from the Federal Food, Drug, and Cosmetic Act (FD&C Act), first enacted in 1938 and substantially amended by the Kefauver-Harris Amendment of 1962, which established the efficacy requirement that still anchors modern approval standards (FDA: FD&C Act).

Scope encompasses small-molecule drugs submitted via a New Drug Application (NDA) and, separately, biological products licensed through a Biologics License Application (BLA). Generic drugs follow a distinct Abbreviated New Drug Application (ANDA) pathway, and over-the-counter (OTC) products operate under a monograph system rather than individual NDAs. The full scope of FDA regulatory authority extends across all these product categories simultaneously.

The process is not a single approval event but a structured sequence of gatekeeping decisions that can span 10 to 15 years from initial discovery to market entry, with an average pre-approval research cost that the Tufts Center for the Study of Drug Development estimated at $2.6 billion per approved compound (Tufts CSDD, 2014).

Core mechanics or structure

Preclinical Development

Before any human exposure, a drug candidate undergoes laboratory and animal testing to characterize pharmacology, toxicology, and pharmacokinetics. CDER does not formally approve preclinical work, but data from this phase must satisfy minimum safety thresholds before an Investigational New Drug (IND) application can proceed.

Investigational New Drug (IND) Application

The IND, filed under 21 CFR Part 312, is the regulatory gateway to human clinical trials. Sponsors submit manufacturing information, preclinical data, and a clinical protocol. The IND becomes effective automatically after 30 days unless FDA places a clinical hold. More than 1,000 INDs are submitted to CDER annually (FDA CDER Annual Report).

Clinical Trials: Three Primary Phases

FDA clinical trials oversight structures human testing into three sequential phases:

• Phase 1: 20–100 healthy volunteers; primary objective is safety, dose-ranging, and pharmacokinetics.
• Phase 2: 100–500 patients with the target condition; evaluates efficacy signals and identifies side effects.
• Phase 3: 1,000–5,000 patients in randomized controlled trials; provides statistically adequate evidence of safety and effectiveness.

Roughly 90 percent of compounds entering Phase 1 fail to reach the NDA stage, a figure cited by the FDA itself in its drug development documentation (FDA: Drug Development Process).

New Drug Application (NDA)

The FDA New Drug Application consolidates all data into a submission reviewed under 21 CFR Part 314. A standard NDA review carries a Prescription Drug User Fee Act (PDUFA) target of 12 months; priority review carries a 6-month target. CDER may convene an independent advisory committee before issuing a final action.

Post-Market Surveillance

Approval is not the endpoint. Phase 4 studies, Risk Evaluation and Mitigation Strategies (REMS), and the MedWatch adverse event reporting system create ongoing obligations. FDA adverse event reporting can trigger label changes, restricted distribution, or withdrawal.

Causal relationships or drivers

Three structural factors determine the pace and outcome of any approval:

1. Evidentiary standards: The 1962 Kefauver-Harris Amendment imposed the "substantial evidence" standard, requiring at least one adequate and well-controlled trial. In practice, CDER typically requires two such trials, though rare disease applications have obtained approval on a single pivotal trial under specific circumstances.

2. User fee agreements: The Prescription Drug User Fee Act (PDUFA), first enacted in 1992 and reauthorized every five years, funds approximately 75 percent of CDER's drug review operations (FDA PDUFA). PDUFA performance goals bind FDA to specific review timelines, directly accelerating approval decisions relative to pre-1992 baselines.

3. Accelerated pathway eligibility: Legislative and regulatory frameworks — including Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review designations — create tiered evidentiary requirements for drugs addressing unmet medical needs. FDA accelerated approval pathways allow conditional approval on surrogate endpoints, with confirmation of clinical benefit required post-approval.

Classification boundaries

Not all drug approvals follow identical requirements. The principal regulatory distinctions:

• NDA vs. BLA: Small-molecule drugs use NDAs; proteins, monoclonal antibodies, and other biologics use BLAs reviewed by CDER (for therapeutic biologics) or the Center for Biologics Evaluation and Research (CBER). See FDA Biologics License Application for the BLA pathway.
• NDA vs. ANDA: Generic drugs demonstrate bioequivalence rather than independent clinical safety and efficacy. The ANDA pathway, established by the Hatch-Waxman Act of 1984, is documented separately at FDA generic drug approval.
• Prescription vs. OTC: Rx drugs require an NDA with full clinical data. OTC drugs sold under an established monograph do not require individual premarket approval. FDA over-the-counter drug regulations governs the monograph system.
• Orphan vs. non-orphan: Drugs targeting diseases affecting fewer than 200,000 U.S. patients qualify for FDA orphan drug designation, conferring seven years of market exclusivity and tax incentives.

Tradeoffs and tensions

The approval process embeds structural conflicts that generate ongoing policy debate:

Speed vs. certainty: Accelerated approval allows market access years earlier on surrogate endpoints, but confirmatory trials are sometimes delayed or never completed. A 2022 analysis by the Office of Inspector General found that 5 of 6 oncology drugs approved via accelerated approval between 2013 and 2017 had outstanding confirmatory trial requirements more than 5 years post-approval (OIG Report OEI-01-21-00130, 2022).

Commercial funding vs. regulatory independence: PDUFA's user-fee structure means pharmaceutical manufacturers fund roughly three-quarters of the drug review process. Critics argue this creates structural pressure toward approval; proponents note that PDUFA performance metrics apply equally to safety reviews.

Rare disease flexibility vs. evidentiary rigor: Orphan drug pathways and single-trial approvals for rare conditions expand patient access but generate post-market uncertainty about actual benefit-risk profiles. The FDA homepage provides direct navigation to current guidance documents on each of these balancing acts.

Label scope vs. off-label use: FDA approves drugs for specific indications, but once marketed, prescribers may use them for any condition. This creates a regulatory perimeter that approval data cannot fully address.

Common misconceptions

Misconception: FDA approval means the drug has no serious risks.
Correction: FDA approves drugs when benefits are determined to outweigh risks for a defined population under defined conditions. Many approved drugs carry black box warnings — the strongest label warning in the U.S. system — documenting serious or life-threatening risks. FDA prescription drug labeling details the labeling framework.

Misconception: Clinical trials test every possible patient population.
Correction: Pivotal trials often enroll narrowly defined populations. Pediatric, geriatric, pregnant, and renally impaired patients are frequently underrepresented. The Best Pharmaceuticals for Children Act and Pediatric Research Equity Act impose mandatory pediatric study requirements for certain products to address this gap.

Misconception: A faster approval process is always a better one.
Correction: Approval speed and post-market label changes are positively correlated in some analyses. Drugs granted priority review have historically had higher rates of post-market safety actions than standard-review drugs, reflecting the tradeoff between early access and complete characterization.

Misconception: FDA tests drugs directly.
Correction: FDA evaluates data submitted by sponsors — it does not conduct trials. The agency's role is evidentiary review, facility inspection, and regulatory decision-making, not experimental pharmacology.

Checklist or steps (non-advisory)

The following represents the documented sequential milestones in a standard NDA pathway, as described in 21 CFR Parts 312 and 314:

1. Preclinical testing completed — pharmacology, toxicology, and ADME characterization in animal models.
2. IND application filed — submitted to CDER under 21 CFR Part 312; 30-day review clock begins.
3. Phase 1 initiated — first-in-human dosing; safety and pharmacokinetics primary endpoints.
4. Phase 2 completed — preliminary efficacy data and dose selection; protocol for Phase 3 agreed with FDA via Special Protocol Assessment if sought.
5. Phase 3 completed — pivotal randomized controlled trials providing substantial evidence of effectiveness.
6. NDA submitted — full data package, proposed labeling, manufacturing data, filed under 21 CFR Part 314.
7. Filing review (60-day) — CDER determines whether application is sufficiently complete to file.
8. Substantive review — CDER multidisciplinary review teams (clinical, statistical, pharmacology, chemistry, clinical pharmacology) evaluate all data.
9. Advisory committee meeting (if convened) — independent expert panel provides non-binding recommendation.
10. PDUFA action date — FDA issues an approval, complete response letter, or other action.
11. Labeling negotiation — sponsor and FDA agree on final prescribing information language.
12. Post-market obligations activated — REMS (if required), Phase 4 commitments, MedWatch reporting.

Reference table or matrix

FDA Drug Approval Pathways: Key Characteristics